Skip to main content
. 2023 Jan 31;6(2):e1056. doi: 10.1002/hsr2.1056

Table 1.

Baseline clinical characteristics of study patients

Characteristic Total (n = 780,785) Candesartan (n = 58,892) Fimasartan (n = 21,041) Irbesartan (n = 37,170) Losartan (n = 298,461) Olmesartan (n = 100,348) Telmisartan (n = 125,730) Valsartan (n = 139,143) p value
Age (years), median (Q1, Q3) 59.0 (52.0, 67.0) 60.0 (53.0, 68.0) 57.0 (50.0, 65.0) 60.0 (54.0, 68.0) 60.0 (54.0, 68.0) 58.0 (52.0, 66.0) 58.0 (52.0, 66.0) 58.0 (52.0, 66.0) <0.001a
Sex <0.001*
Male, n (%) 442,694 56.7 32,448 55.1 11,819 56.2 20,220 54.4 160,732 53.9 58,953 58.8 76,198 60.6 82,324 59.2
Female, n (%) 338,091 43.3 26,444 44.9 9,222 43.8 16,950 45.6 137,729 46.2 41,395 41.3 49,532 39.4 56,819 40.8
BMI (kg/m²), median (Q1, Q3) 25.2 (23.2, 27.3) 25.1 (23.2, 27.1) 25.1 (23.2, 27.2) 25.1 (23.2, 27.1) 25.0 (23.1, 27.1) 25.4 (23.5, 27.5) 25.3 (23.4, 27.4) 25.2 (23.3, 27.4) <0.001a
SBP (mmHg), median (Q1, Q3) 130.0 (120.0, 138.0) 129.0 (120.0, 137.0) 128.0 (119.0, 136.0) 130.0 (120.0, 138.0) 130.0 (120.0, 139.0) 128.0 (120.0, 136.0) 129.0 (120.0, 137.0) 130.0 (120.0, 139.0) <0.001a
DBP (mmHg), median (Q1, Q3) 80.0 (72.0, 85.0) 80.0 (70.0, 84.0) 80.0 (71.0, 85.0) 80.0 (71.0, 85.0) 80.0 (72.0, 85.0) 80.0 (70.0, 84.0) 80.0 (71.0, 85.0) 80.0 (73.0, 86.0) <0.001a
Diabetes (yes), n (%) 190,528 24.4 16,370 27.8 4,435 21.1 11,532 31.0 71,122 23.8 23,475 23.4 29,727 23.6 33,867 24.3 <0.001*
Dyslipidemia (Yes), n (%) 398,485 38.2 26,728 45.4 8,608 40.9 16,616 44.7 105,665 35.4 36,678 36.6 47,678 37.9 56,512 40.6 <0.001*
Smoke (yes), n (%) 143,226 18.3 9,701 16.5 3,946 18.8 5,828 15.7 51,707 17.3 19,598 19.5 24,918 19.8 27,528 19.8 <0.001*
Drink (yes), n (%) 233,103 29.9 15,814 26.9 6,370 30.3 9,860 26.5 83,784 28.1 32,402 32.3 40,831 32.5 44,042 31.7 <0.001*
Physical activity (yes), n (%) 287,360 36.8 21,311 36.2 7,852 37.3 13,193 35.5 111,244 37.3 36,712 36.6 45,923 36.5 51,125 36.7 <0.001*
Income quartiles <0.001*
Lowest, n (%) 158,555 20.3 11,338 19.3 4,335 20.6 7,182 19.3 63,322 21.2 20,103 20.0 24,845 19.8 27,430 19.7
Second, n (%) 141,405 18.1 9,910 16.8 3,883 18.5 6,184 16.6 55,782 18.7 18,126 18.1 22,701 18.1 24,819 17.8
Third, n (%) 185,401 23.8 13,419 22.8 5,100 24.2 8,501 22.9 71,642 24.0 23,985 23.9 29,478 23.5 33,276 23.9
Highest, n (%) 295,424 37.8 24,225 41.1 7,723 36.7 15,303 41.2 107,715 36.1 38,134 38.0 48,706 38.7 53,618 38.5
FBS (mg/dl), median (Q1, Q3) 101.0 (92.0, 116.0) 102.0 (92.0, 116.0) 100.0 (91.0, 113.0) 102.0 (93.0, 119.0) 101.0 (92.0, 116.0) 102.0 (92.0, 116.0) 102.0 (93.0, 116.0) 101.0 (92.0, 116.0) <0.001a
Total cholesterol (mg/dl), median (Q1, Q3) 186.0 (163.0, 212.0) 182.0 (158.0, 208.0) 186.0 (163.0, 211.0) 182.0 (158.0, 207.0) 187.0 (164.0, 212.0) 188.0 (164.0, 214.0) 188.0 (164.0, 213.0) 185.0 (161.0, 211.0) <0.001a
HDL (mg/dl), median (Q1, Q3) 50.0 (43.0, 60.0) 50.0 (43.0, 60.0) 51.0 (43.0, 60.0) 50.0 (42.0, 59.0) 51.0 (43.0, 60.0) 50.0 (43.0, 59.0) 50.0 (42.0, 59.0) 50.0 (43.0, 60.0) <0.001a
LDL (mg/dl), median (Q1, Q3) 106.0 (84.0, 129.0) 102.0 (80.0, 126.0) 105.0 (83.0, 128.0) 102.0 (81.0, 125.0) 106.0 (85.0, 130.0) 107.0 (84.0, 131.0) 107.0 (84.0, 131.0) 104.0 (82.0, 128.0) <0.001a
TG (mg/dl), median (Q1, Q3) 124.0 (88.0, 179.0) 122.0 (87.0, 174.0) 123.0 (87.0, 178.0) 121.0 (86.0, 173.0) 124.0 (88.0, 177.0) 128.0 (90.0, 184.0) 125.0 (89.0, 180.0) 125.0 (88.0, 180.0) <0.001a
GFR (ml/min), median (Q1, Q3) 81.0 (70.0, 94.0) 81.0 (69.0, 94.0) 82.0 (71.0, 96.0) 80.0 (68.0, 93.0) 81.0 (69.0, 93.0) 81.0 (70.0, 94.0) 82.0 (71.0, 96.0) 82.0 (71.0, 95.0) <0.001a
Proteinuria <0.001*
Negative (−), n (%) 725,690 92.9 54,556 92.6 19,946 94.8 33,643 90.5 278,075 93.2 93,991 93.7 117,165 93.2 128,314 92.2
Trace (±), n (%) 23,719 3.0 1880 3.2 520 2.5 1312 3.5 8901 3.0 2859 2.9 3707 3.0 4540 3.3
Positive (+1), n (%) 18,836 2.4 1,448 2.5 366 1.7 1182 3.2 7136 2.4 2148 2.1 2848 2.3 3708 2.7
Positive (+2), n (%) 9162 1.2 744 1.3 162 0.8 705 1.9 3251 1.1 967 1.0 1455 1.2 1878 1.4
Positive (+3), n (%) 2783 0.36 219 0.37 39 0.19 263 0.71 908 0.30 322 0.32 462 0.37 570 0.41
Positive (+4), n (%) 595 0.08 45 0.08 8 0.04 65 0.17 190 0.06 61 0.06 93 0.07 133 0.10
Calcium channel blockers (yes), n (%) 175,253 22.5 16,224 27.6 4219 20.1 11,023 29.7 80,508 27.0 18,771 18.7 18,162 14.5 26,346 18.9 <0.001*
Beta‐blockers (yes), n (%) 68,705 8.8 6245 10.6 1288 6.1 3904 10.5 24,380 8.2 8044 8.0 10,233 8.1 14,611 10.5 <0.001*
ACEIs (yes), n (%) 4060 0.52 341 0.58 142 0.67 237 0.64 1280 0.43 474 0.47 592 0.47 994 0.71 <0.001*
Diuretics (yes), n (%) 47,779 6.1 3302 5.6 1485 7.1 2046 5.5 17,074 5.7 5616 5.6 8070 6.4 10,186 7.3 <0.001*
Antithrombotic agents (yes), n (%) 204,531 26.2 16,825 28.6 4,270 20.3 11,593 31.2 78,708 26.4 26,611 26.5 30,908 24.6 35,616 25.6 <0.001*
Statins (yes), n (%) 239,239 30.6 22,323 37.9 6725 32.0 13,422 36.1 84,854 28.4 28,848 28.8 37,632 29.9 45,435 32.7 <0.001*

Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; BMI, body mass index; DBP, diastolic blood pressure; FBS, fasting blood sugar; GFR, glomerular filtration rate; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; SBP, systolic blood pressure; TG, triglyceride.

a

p value was obtained using χ 2 test.

*

p value was obtained using the Kruskal–Wallis test.